The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 357:1153-1154 September 13, 2007 Number 11
NextNext

Eprodisate in AA Amyloidosis

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Dember, L. M.
-Related Article
by Lachmann, H. J.
-PubMed Citation
To the Editor: Dember et al. (June 7 issue)1 report that eprodisate slows the deterioration of renal function in patients with AA amyloidosis. However, they do not mention the use of colchicine in patients with familial Mediterranean fever–related AA amyloidosis (19% of their study population). In a related article, Lachmann et al.2 report that patients with AA amyloidosis associated with familial Mediterranean fever were treated with colchicine. The beneficial effects of colchicine in these patients have led to its use for amyloidosis secondary to other causes, which is why we believe that colchicine therapy was probably also given to a . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.